Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C22H21ClN2O8 |
| Molecular Weight | 476.864 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)[C@H]1[C@@H]2[C@@H](O)[C@@H]3C(=C)C4=C(Cl)C=CC(O)=C4C(=O)C3=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O
InChI
InChIKey=GGQJXCQBBONZFX-IWVLMIASSA-N
InChI=1S/C22H21ClN2O8/c1-6-9-7(23)4-5-8(26)11(9)16(27)12-10(6)17(28)14-15(25(2)3)18(29)13(21(24)32)20(31)22(14,33)19(12)30/h4-5,10,14-15,17,26,28-30,33H,1H2,2-3H3,(H2,24,32)/t10-,14-,15+,17+,22+/m1/s1
| Molecular Formula | C22H21ClN2O8 |
| Molecular Weight | 476.864 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Meclocycline is a tetracycline antibiotic. It is used topically for skin infections treatment. Tetracyclines are broad-spectrum bacteriostatic agents and act by inhibiting protein synthesis by blocking the binding of aminoacyl tRNA (transfer RNA) to the mRNA (messenger RNA) ribosome complex. Meclocycline might increase sensitivity to light when it is used with Aminolevulinic acid.
Originator
Approval Year
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 12-37 |
Other AEs: Yellow skin... |
1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Other AEs: Contact dermatitis... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Yellow skin | 6% | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy, 12-37 |
| Contact dermatitis | 1 % 2 times / day multiple, topical Recommended Dose: 1 %, 2 times / day Route: topical Route: multiple Dose: 1 %, 2 times / day Sources: |
unhealthy |
Sample Use Guides
In Vivo Use Guide
Curator's Comment: Noticeable improvement may be seen in 4 to 6 weeks. In some patients it may require up to 6 to 8 weeks of treatment before noticeable improvement is seen and up to 8 to 12 weeks before maximum benefit is seen.
Two times a day, morning and evening.
Route of Administration:
Topical
| Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 08:46:53 GMT 2025
by
admin
on
Wed Apr 02 08:46:53 GMT 2025
|
| Record UNII |
23Q8M2HE6S
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1595
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
||
|
WHO-ATC |
D10AF04
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
||
|
WHO-VATC |
QD10AF04
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
29418
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | RxNorm | ||
|
3333
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
C100122
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
1566
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
SUB08677MIG
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
MECLOCYCLINE
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
23Q8M2HE6S
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
DTXSID4048567
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
100000081776
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
217-938-3
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
C61825
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
CHEMBL1237124
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
m7119
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB13092
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
2013-58-3
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY | |||
|
78502
Created by
admin on Wed Apr 02 08:46:53 GMT 2025 , Edited by admin on Wed Apr 02 08:46:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |